Neutrophil to Lymphocyte Ratio and Outcomes in Patients with New-Onset or Worsening Heart Failure with Reduced and Preserved Ejection Fraction by Curran, Fraser M. et al.
                                                                    
University of Dundee
Neutrophil to Lymphocyte Ratio and Outcomes in Patients with New-Onset or
Worsening Heart Failure with Reduced and Preserved Ejection Fraction









Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Curran, F. M., Bhalraam, U., Mohan, M., Singh, J. S., Anker, S. D., Dickstein, K., Doney, A. S., Filippatos, G.,
George, J., Metra, M., Ng, L. L., Palmer, C. N., Samani, N. J., van Veldhuisen, D. J., Voors, A. A., Lang, C. C., &
Mordi, I. R. (2021). Neutrophil to Lymphocyte Ratio and Outcomes in Patients with New-Onset or Worsening
Heart Failure with Reduced and Preserved Ejection Fraction. ESC Heart Failure.
https://doi.org/10.1002/ehf2.13424
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 29. May. 2021
Neutrophil-to-lymphocyte ratio and outcomes in
patients with new-onset or worsening heart failure
with reduced and preserved ejection fraction
Fraser M. Curran1†, U Bhalraam1†, Mohapradeep Mohan2, Jagdeep S. Singh2, Stefan D. Anker3,
Kenneth Dickstein4, Alexander S. Doney5, Gerasimos Filippatos6, Jacob George2, Marco Metra7, Leong L. Ng8,
Colin N. Palmer5, Nilesh J. Samani8, Dirk J. van Veldhuisen9, Adriaan A. Voors9, Chim C. Lang2
and Ify R. Mordi2*
1School of Medicine, University of Dundee, Dundee, UK; 2Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK; 3Department of Cardiology (CVK);
and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin
Berlin, Berlin, Germany; 4University of Bergen, Stavanger University Hospital, Stavanger, Norway; 5Division of Population Health and Genomics, University of Dundee,
Dundee, UK; 6Heart Failure Unit, Department of Cardiology, School of Medicine, National and Kopodistrian University of Athens, Athens University Hospital Attikon, Athens,
Greece; 7Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; 8Department of
Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK; and 9Department of Cardiology, University Medical Center
Groningen, University of Groningen, Groningen, The Netherlands
Abstract
Aims Inflammation is thought to play a role in heart failure (HF) pathophysiology. Neutrophil-to-lymphocyte ratio (NLR) is a
simple, routinely available measure of inflammation. Its relationship with other inflammatory biomarkers and its association
with clinical outcomes in addition to other risk markers have not been comprehensively evaluated in HF patients.
Methods We evaluated patients with worsening or new-onset HF from the BIOlogy Study to Tailored Treatment in Chronic
Heart Failure (BIOSTAT-CHF) study who had available NLR at baseline. The primary outcome was time to all-cause mortality or
HF hospitalization. Outcomes were validated in a separate HF population.
Results 1622 patients were evaluated (including 523 ventricular ejection fraction [LVEF] < 40% and 662 LVEF ≥ 40%). NLR
was significantly correlated with biomarkers related to inflammation as well as NT-proBNP. NLR was significantly associated
with the primary outcome in patients irrespective of LVEF (hazard ratio [HR] 1.18 per standard deviation increase; 95% con-
fidence interval [CI] 1.11–1.26, P < 0.001). Patients with NLR in the highest tertile had significantly worse outcome than those
in the lowest independent of LVEF (<40%: HR 2.75; 95% CI 1.84–4.09, P < 0.001; LVEF ≥ 40%: HR 1.51; 95% CI 1.05–2.16,
P = 0.026). When NLR was added to the BIOSTAT-CHF risk score, there were improvements in integrated discrimination index
(IDI) and net reclassification index (NRI) for occurrence of the primary outcome (IDI + 0.009; 95% CI 0.00–0.019, P = 0.030;
continuous NRI + 0.112, 95% CI 0.012–0.176, P = 0.040). Elevated NLR was similarly associated with adverse outcome in
the validation cohort. Decrease in NLR at 6 months was associated with reduced incidence of the primary outcome (HR
0.75; 95% CI 0.57–0.98, P = 0.036).
Conclusions Elevated NLR is significantly associated with elevated markers of inflammation in HF patients and is associated
with worse outcome. Elevated NLR might potentially be useful in identifying high-risk HF patients and may represent a treat-
ment target.
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Introduction
There has been long-standing interest in the role of inflamma-
tion in the pathophysiology of heart failure (HF).1 It has been
shown that both heart with reduced ejection fraction (HFrEF)
and heart with preserved ejection fraction (HFpEF) are associ-
ated with elevations in biomarkers related to inflammatory
processes, although the exact mechanisms by which inflam-
mation is thought to contribute towards incidence and prog-
nosis of HF are not fully understood.2,3 It is hypothesized
that the immune system has a key role in initiating an inflam-
matory response that is, at least in part, cardioprotective in
the short term, but, if sustained, can lead to a state of chronic
low-grade inflammation, which may accelerate disease
progression.2 Several studies have highlighted the association
between raised inflammatory biomarkers and adverse out-
comes in HF.3–8 However, none of these biomarkers have been
translated to measurement in routine clinical practice.
Neutrophil-to-lymphocyte ratio (NLR) is a simple marker of
inflammation obtained from routine complete blood counts
that predicts prognosis in a variety of cardiovascular
diseases.9–12 Elevated NLR or individual components are asso-
ciated with worse outcome in patients with acute decompen-
sated HF and HF patients awaiting transplant13–16; however,
its prognostic value has not been adequately characterized
in a well-defined cohort of HFrEF and HFpEF patients with
new-onset or worsening symptoms. Furthermore, no study
has elucidated the relationship of NLR to other established in-
flammatory biomarkers in HF patients. As a marker represen-
tative of several pathways of systemic inflammation, the
concept of NLR acting as a single, routinely available inflam-
matory biomarker is particularly attractive.
The aims of this study were to evaluate the association of
NLR with biomarkers related to various inflammatory path-
ways in patients with HF, to determine its association with
outcomes in both HFrEF and HFpEF in two independent co-




The primary study cohort included participants from the
validation cohort of the Systems Biology Study to Tailored
Treatment in Chronic Heart Failure (BIOSTAT-CHF). The
full details of BIOSTAT-CHF validation cohort including inclu-
sion/exclusion criteria have been published previously.17 In
brief, BIOSTAT-CHF was a multicentre, prospective, observa-
tional study that included both an index cohort of 2516
chronic HF patients with worsening signs and/or symptoms
from 11 European countries, who were considered to be on
suboptimal medical treatment, and a validation cohort of
1738 HF patients was recruited from six centres in Scotland.
The recruitment period started in October 2010 and was
completed in April 2014. NLR was only measured in the vali-
dation cohort of BIOSTAT-CHF, and so, this cohort acted as
the primary cohort for this study. Inclusion criteria for the
BIOSTAT-CHF validation cohort were patients ≥18 years old
with diagnosed HF with either echocardiographic evidence
of left ventricular systolic dysfunction or a previous docu-
mented admission to hospital with HF requiring furosemide,
currently treated with furosemide ≥20 mg/day or equivalent,
and not previously treated or receiving ≤50% of target doses
of ACEI/ARB and/or beta-blocker according to the 2008 ESC
guidelines.18 Patients with acute myocarditis were excluded.
Patients were recruited from both the inpatient and outpa-
tient setting. BIOSTAT-CHF complied with the Declaration of
Helsinki, medical ethics committees of participating centres
approved the study, and all participants provided written in-
formed consent prior to participation.
Available medical history, demographics, current medica-
tions, lab measurements including full blood counts (FBC)
and a panel of biomarkers were obtained at the baseline visit.
Ninety-two biomarkers related to cardiovascular processes
were evaluated using the Olink Cardiovascular and Oncology
panels as previously described.19 Measurement of these bio-
markers was performed by Olink Bioscience analysis service
using the Proseek Multiplex Inflammatory 96 × 96 kit, with ad-
ditional real-time PCR for further quantification. For this study,
we focussed on biomarkers primarily related to inflammation,
summarized in Table S1.20 NLR was calculated from baseline
FBC. There were no patients with known active haematologi-
cal malignancy recorded; however, as data on malignancy (in
particularly haematological malignancy) were not routinely
obtained,21 we excluded patients with a lymphocyte
count > 8 × 109/L on the assumption that this might be sug-
gestive of an undiagnosed haematological condition. Echocar-
diographic data were used to stratify patients into reduced
(LVEF < 40%) and preserved (LVEF ≥ 50%) ejection fraction.
Validation cohort
The validation cohort for this study included participants
from the Genetics of Diabetes and Audit Research Tayside
Scotland (GoDARTS). The full details of the GoDARTS study
have been published previously.22 Briefly, GoDARTS is a data-
base consisting of 18 306 participants (10 149 with Type 2 di-
abetes and 8157 healthy controls) from Tayside (Scotland,
UK). The presence or absence of HF at baseline was not a
criteria for inclusion or exclusion. Baseline data were col-
lected on all patients including prescription data, echocardi-
ography reports, demographic data and clinical variables.
Patient data are linked back as far as 1987 through Commu-
nity Health Index number. Collection and analysis of GoDARTS
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data was approved by the East of Scotland Research Ethics
committee, in compliance with the Declaration of Helsinki.
Patients who survived to 30 days following their first re-
corded HF hospitalization (ICD-10 code I50) were included
in this study. NLR was calculated from FBC taken nearest
the time of hospitalization. Baseline clinical, demographic
and prescription data were obtained from electronic health
records. Patients underwent echocardiography for clinical in-
dications, and ejection fraction where available was used to
stratify patients into those with reduced and preserved
LVEF.23 LVEF was not always measured using Simpson’s
method in these clinical reports, so conversion of qualitative
assessment of LVEF was made using the 2011 ACCF/AHA
criteria,24 where moderate or severe left ventricular systolic
dysfunction was estimated to be LVEF < 40%.
Clinical outcomes
The primary outcome was all-cause mortality and/or HF hos-
pitalization. In BIOSTAT-CHF, all deaths and hospitalizations
were recorded by the local investigator,25 with death and
HF hospitalization outcome data also supplemented by elec-
tronic health records using ICD-10 coding (I50) from the Scot-
tish Morbidity Record (SMR) and General Register Office
Scotland (GRO). In GoDARTS, all clinical outcomes were ob-
tained from electronic health record data using the SMR
and GRO. Time to death or subsequent HF hospitalization fol-
lowing the index HF hospitalization was ascertained. In both
cases, outcomes were not centrally adjudicated.
Statistical analysis
Baseline variables and clinical outcomes were recorded and
categorized by the median NLR. Continuous variables were
reported as mean ± standard deviation (SD) or median and
interquartile range and categorical data as number and
percentage. Correlations between NLR and biomarkers were
determined using the Spearman correlation. The association
between NLR and the primary outcome was determined
using survival analysis (Cox proportional hazard model and
Kaplan–Meier analysis) adjusting for the BIOSTAT-CHF risk
prediction model, which includes age, HF hospitalization in
the previous year, peripheral oedema, systolic blood pres-
sure, estimated glomerular filtration rate, urea, N-terminal
pro-brain natriuretic peptide, haemoglobin, high-density lipo-
protein cholesterol, sodium and beta-blocker use.26 This
model performed similarly in both HFrEF and HFpEF with
C-statistics for prediction of the primary outcome of 0.68 in
HFrEF and 0.69 in HFpEF. The cohort was further stratified
into tertiles of NLR to determine the stepwise association
with increasing NLR and the primary outcome. We conducted
interaction tests to see if the association between NLR and
outcomes differed based on ejection fraction and place of re-
cruitment (i.e. patients recruited from the inpatient vs. out-
patient setting). As ejection fraction was not available in the
whole BIOSTAT cohort, we performed sensitivity analyses ex-
cluding those without available ejection fraction. In BIOSTAT,
we have also found several other biomarkers, specifically
cancer antigen 125 (CA-125),27 fibroblast growth factor 23
(FGF-23),28 bioadrenomedullin29 and interleukin 6,30 that
have been associated with adverse outcomes; therefore, we
also conducted an analysis to determine the association of
NLR with outcomes after adjustment for these biomarkers.
As NLR has previously been shown to be associated with
markers of congestion, we also performed a multivariable
analysis with adjustment for pulmonary congestion, hepato-
megaly and elevated jugular venous pressure in addition to
the BIOSTAT-CHF risk model. Finally, NLR was added to
BIOSTAT-CHF risk score, and improvements in predictive ca-
pability were assessed using C-statistic, integrated discrimina-
tion index (IDI) and net reclassification index (NRI).
A Cox proportional hazard model and Kaplan–Meier analy-
sis were used to determine the association between NLR and
the primary outcome in the validation cohort. As not all
variables required for the BIOSTAT-CHF risk model were
available, a pragmatic multivariable adjustment for age,
gender, diabetes, cholesterol, blood pressure, smoking status,
ACEI/ARB and beta-blocker use at the time of diagnosis and
prior myocardial infarction was used. Statistical analyses
were performed using SPSS Version 22.0 and R Version
3.5.1. A P-value < 0.05 was considered significant.
Results
Primary cohort (BIOSTAT-CHF): Baseline
characteristics
In total, 1625 patients had NLR measured in the BIOSTAT co-
hort. Of these, three patients had a lymphocyte count above
8 × 109/L and thus were excluded from analysis in case this
represented an undiagnosed haematological condition.
Baseline characteristics of the 1622 patients analysed are
summarized in Table 1. The mean age of the cohort was
74 ± 10 years, and the majority of patients were male
(67%). Patients were predominantly NYHA Classes 2–3
(86%) and had ischaemic HF aetiology (65%). There were
890 patients with LVEF < 40% (HFrEF) and 526 with
LVEF ≥ 50% (HFpEF). As per study inclusion criteria, almost
all patients were receiving loop diuretics, whereas 70.8%
were receiving an ACEI/ARB and 73.2% were on beta-blocker
therapy. The median NLR was 3.22. Patients with NLR above
the median value were older and more likely to be male. De-
spite having a shorter duration of HF, they also had higher
NT-proBNP and were more symptomatic with higher NYHA
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class and more clinical congestion. They were also less likely
to be taking ACEI/ARB or beta-blockers than patients with
NLR below the median (ACEI/ARB: 65.6% vs. 75.9%,
P < 0.001; beta-blockers: 69.7% vs. 76.8%, P = 0.002). There
were no significant differences in most baseline
comorbidities, although they were more likely to have renal
impairment. Eight hundred forty-seven patients were re-
cruited from the inpatient setting, whereas 778 were outpa-
tients with worsening HF; NLR was significantly higher in
inpatients than outpatients (4.69 vs. 3.33, P < 0.001).






(n = 815) P-value
Demographics
Age (years) 74 ± 10 72 ± 11 75 ± 11 <0.001
Female 536 (33.0) 300 (37.2) 236 (29.0) <0.001
Current smoker 562 (34.6) 269 (33.3) 293 (36.0) 0.14
BMI (kg/m2) 29.1 ± 6.4 29.7 ± 6.3 28.6 ± 6.4 0.001
Clinical profile
NYHA class, % <0.001
I 16 (1.0) 6 (0.7) 10 (1.2)
II 680 (41.9) 413 (51.2) 267 (32.8)
III 713 (44.0) 326 (40.4) 387 (47.5)
IV 212 (13.1) 61 (7.6) 151 (18.5)
Duration of HF (years) 5.3 ± 4.7 5.6 ± 4.7 5.0 ± 4.7 0.017
Ischaemic aetiology of HF 1,056 (65.1) 530 (65.7) 526 (64.5) 0.64
Systolic blood pressure, (mmHg) 125 ± 21 126 ± 22 125 ± 23 0.50
Diastolic blood pressure (mmHg) 69 ± 12 70 ± 12 68 ± 14 0.003
Heart rate (bpm) 76 ± 22 74 ± 21 78 ± 22 <0.001
Inpatient 847 (52.2) 340 (42.1) 507 (62.2) <0.001
Elevated jugular venous pressure 422 (26.0) 162 (20.1) 260 (31.9) <0.001
Pulmonary congestion 661 (40.8) 252 (31.2) 409 (50.2) <0.001
Hepatomegaly 58 (3.6) 20 (2.5) 38 (4.7) 0.032
Peripheral oedema 885 (54.6) 374 (46.3) 511 (62.7) <0.001
Echocardiographic measurements
Left ventricular ejection fraction (%) 41 ± 14 40 ± 13 41 ± 14 0.76
LVEF < 40% 523 (32.2) 255 (31.6) 268 (32.9)
LVEF ≥ 40% 662 (40.8) 315 (39.0) 347 (42.6)
No LVEF available 437 (26.9) 237 (29.4) 200 (24.5)
Past medical history
Myocardial infarction 794 (49.0) 395 (48.9) 399 (49.0) 0.96
Atrial fibrillation 713 (44.0) 340 (42.1) 373 (45.8) 0.17
Diabetes mellitus 522 (32.2) 251 (31.1) 271 (33.3) 0.34
Hypertension 937 (57.8) 449 (55.6) 488 (59.9) 0.09
Device therapy 0.73
Pacemaker 109 (6.7) 55 (6.8) 54 (6.6)
ICD 65 (4.0) 28 (3.5) 37 (4.5)
CRT 79 (4.9) 37 (4.6) 42 (5.2)
Medication
ACEI/ARB 1,148 (70.8) 613 (76.0) 535 (65.6) <0.001
Beta-blockers 1,188 (73.2) 620 (76.8) 568 (69.7) 0.001
Aldosterone antagonists 528 (32.6) 252 (31.2) 276 (33.9) 0.28
Loop diuretics 1,574 (97.0) 783 (97.0) 791 (97.1) >0.99
Laboratory measurements
Creatinine (μmol/L) 111 ± 45 102 ± 42 118 ± 55 <0.001
Urea (mmol/L) 8.6 (6.0–11.3) 8.4 (5.9–11.0) 8.8 (6.0–11.7) 0.12
Estimated glomerular filtration rate (ml/min/1.73 m2)a <0.001
≥60 855 (52.7) 481 (59.6) 374 (45.9)
45–59 371 (22.9) 178 (22.1) 193 (23.7)
<45 393 (24.2) 145 (18.0) 248 (30.4)
NT-proBNP (ng/L) 1243 (0–2670) 834 (0–1684) 2065 (0–4319) <0.001
Neutrophils (109/L) 5.4 ± 2.6 4.4 ± 1.4 6.5 ± 3.0 <0.001
Lymphocytes (109/L) 1.6 ± 0.9 2.0 ± 1.1 1.2 ± 0.5 <0.001
Haemoglobin (g/d) 15.1 ± 2.7 15.8 ± 2.5 14.5 ± 2.8 0.08
Platelets (109/L) 245 ± 92 236 ± 81 253 ± 101 <0.001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CRT, cardiac resynchronization therapy; ICD, implant-
able cardioverter defibrillator.
Bold indicates P < 0.05. Continuous variables reported as mean ± standard deviation or median (interquartile range), and categorical var-
iables as number (percentage).
aThree patients in NLR < 3.22 group did not have eGFR measured.
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Correlations between NLR and biomarkers
related to inflammation
Correlations between NLR and biomarkers are summarized in
Figure 1. NLR was most strongly associated with interleukin 6
(ρ = 0.41), bio-adrenomedullin (ρ = 0.40), sST2 (ρ = 0.39), NT-
proBNP (ρ = 0.38), tumour necrosis factor (TNF) receptor 1
(ρ = 0.35), CA-125 (ρ = 0.32) and TNF receptor 2 (ρ = 0.30),
all P < 0.001. Biomarker correlations were similar stratified
by LVEF ( Figure S1).
Association between NLR and clinical outcomes in
BIOSTAT-CHF
Associations between NLR and outcomes in the primary co-
hort are summarized in Table 2. Over the median follow-up
period of 18 months, the primary outcome occurred in 667
individuals, including 447 deaths and 406 HF hospitalizations.
After adjustment for the BIOSTAT-CHF risk prediction model,
NLR was significantly associated with increased incidence of
the primary outcome (hazard ratio [HR] 1.18 per SD increase;
95% confidence interval [CI] 1.11–1.25, P < 0.001). Both ele-
vated neutrophil count (HR 1.11 per SD increase; 95% CI
1.04–1.19, P = 0.002) and lower lymphocyte count (HR 0.85
per SD increase; 95% CI 0.76–0.95, P = 0.005) were also asso-
ciated with the primary outcome. NLR was also significantly
associated with increased all-cause mortality (HR 1.37; 95%
CI 1.30–1.44, P < 0.001).
There was no significant interaction between NLR and LVEF
category (<40% or ≥40%) for the association with the primary
outcome (P = 0.06) or mortality (P = 0.27), with NLR signifi-
cantly associated with the primary outcome in patients with
LVEF < 40% (HR 1.24; 95% CI 1.12–1.35, P < 0.001), though
the association did not quite reach statistical significance in
patients with LVEF ≥40% (HR 1.10; 95% CI 0.99–1.23,
P = 0.07). NLR was more strongly associated with the primary
outcome in outpatients than those recruited as inpatients (HR
1.48; 95% CI 1.30–1.69, P < 0.001 vs. 1.11; 95% CI 1.03–1.19,
P = 0.005, respectively; interaction P-value < 0.001). In a
model including the BIOSTAT risk score and NT-proBNP as
an additional variable, NLR remained associated with both
the primary outcome (HR 1.17; 9% CI 1.10–1.24, P < 0.001)
and mortality only (HR 1.32; 95% CI 1.25–1.40, P < 0.001).
Figure 1 Correlation matrix of NLR, NT-proBNP and biomarkers of inflammation. Correlation matrix showing Spearman correlation of biomarkers.
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When the cohort was stratified into tertiles of NLR, after
adjustment for the BIOSTAT-CHF risk score, there was a
significant stepwise association between higher NLR and
increased likelihood of the primary outcome (Tertile 2: HR
1.33; 95% CI 1.06–1.67, P = 0.014; Tertile 3: HR 1.72;
95% CI 1.37–2.15, P < 0.001) (Figure 2), with similar results
for mortality alone. Results followed a similar pattern when
the cohort was stratified by LVEF, with patients in the
highest tertile having worse outcome regardless of LVEF
(LVEF < 40%: HR 2.75; 95% CI 1.84–4.09, P < 0.001;
LVEF ≥ 40%: HR 1.51; 95% CI 1.05–2.16, P = 0.026).
This pattern was similar in patients with unknown LVEF
(Table S2).
NLR remained significantly associated with the primary
outcome after additional adjustment for markers of conges-
tion (HR 1.22; 95% CI 1.14–1.31, P < 0.001).
There was no significant interaction with HF treatment at
baseline in patients with LVEF < 40% for the association be-
tween NLR and the primary outcome (ACEI/ARB P = 0.22;
beta-blocker P = 0.44; MRA P = 0.29).
When NLR was added to the BIOSTAT-CHF risk score, there
was a marginal increase in C-statistic for prediction of the
primary outcome from 0.716 to 0.72 but no difference in
mortality (0.755–0.754). In contrast, the C-statistic for
prediction of the primary outcome when neutrophils or lym-
phocytes were individually added to the BIOSTAT-CHF risk
Table 2 Association between neutrophil count, lymphocyte count, NLR and outcomes in BIOSTAT-CHF







Mortality and/or HF hospitalization
Neutrophil count per SD increase 1.11 (1.04–1.20) 0.001 1.24 (1.12–1.37) <0.001 1.02 (0.91–1.14) 0.72
Lymphocyte count per SD increase 0.74 (0.65–0.85) <0.001 0.59 (0.46–0.75) <0.001 0.81 (0.65–0.99) 0.041
NLR per SD increase 1.18 (1.11–1.26) <0.001 1.24 (1.12–1.35) <0.001 1.10 (0.99–1.23) 0.07
NLR Tertile 1 Baseline Baseline Baseline
NLR Tertile 2 1.33 (1.06–1.67) 0.014 1.98 (1.30–3.01) 0.001 1.12 (0.87–1.46) 0.42
NLR Tertile 3 1.72 (1.37–2.15) <0.001 2.75 (1.84–4.09) <0.001 1.51 (1.05–2.16) 0.026
Mortality
Neutrophil count per SD increase 1.21 (1.14–1.29) <0.001 1.46 (1.31–1.63) <0.001 1.03 (0.90–1.17) 0.69
Lymphocyte count per SD increase 0.40 (0.33–0.48) <0.001 0.36 (0.26–0.49) <0.001 0.58 (0.44–0.76) <0.001
NLR per SD increase 1.38 (1.30–1.46) <0.001 1.38 (1.26–1.51) <0.001 1.18 (1.06–1.33) 0.004
NLR Tertile 1 Baseline Baseline Baseline
NLR Tertile 2 2.14 (1.55–2.95) <0.001 4.06 (2.16–7.60) <0.001 1.51 (0.92–2.48) 0.10
NLR Tertile 3 4.14 (3.10–5.55) <0.001 7.71 (4.32–13.76) <0.001 2.30 (1.44–3.68) <0.001
All hazard ratios adjusted for the BIOSTAT-CHF risk model, which includes age, HF hospitalization in the previous year, peripheral oedema,
systolic blood pressure, estimated glomerular filtration rate, urea, N-terminal pro-brain natriuretic peptide, haemoglobin, high-density li-
poprotein cholesterol, sodium and beta-blocker use.
Bold indicates P < 0.05.
Figure 2 Outcomes stratified by tertiles of NLR in the BIOSTAT-CHF cohort. Kaplan–Meier analysis of mortality/HF hospitalization stratified by NLR
tertile in the whole BIOSTAT-CHF cohort and in those with HFrEF and HFpEF.
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score was unchanged at 0.716. There were significant im-
provements in IDI and continuous NRI at 2 years with addi-
tion of NLR to the BIOSTAT risk model for both the primary
outcome (IDI 0.009; 95% CI 0.00–0.019, P = 0.030; continuous
NRI 0.112, 95% CI 0.012–0.176, P = 0.040) and for mortality
alone (IDI 0.050; 95% CI 0.031–0.072, P < 0.001; continuous
NRI 0.282, 95% CI 0.227–0.340, P < 0.001).
Association of NLR and outcomes compared with
other biomarkers
After adjustment for the BIOSTAT-CHF risk score and bio-
markers related to inflammation that were also associated
with the primary outcome at P < 0.005 (cystatin B, interleu-
kins 1, 6 and 17, osteoprotegerin, TNF receptors 1 and 2 and
TNF receptor superfamily members 13B and 14), NLR
remained significantly associated with the primary outcome
(HR 1.17; 95% CI 1.09–1.25, P < 0.001) as summarized in
Table 3.
In a separate model adjusted for the BIOSTAT-CHF risk
score, NT-proBNP, CA-125, FGF-23, bio-adrenomedullin and
interleukin 6, NLR remained significantly associated with both
the primary outcome (HR 1.13; 95% CI 1.04–1.20, P = 0.002)
and mortality alone (HR 1.14; 95% CI 1.07–1.23, P < 0.001)
(Table S3).
Validation cohort (GoDARTS): Baseline
characteristics
In total, 1013 patients were available for analysis from the
GoDARTS cohort. Again, three were excluded as they had a
lymphocyte count > 8 × 109/L. Baseline characteristics are
summarized in Table S4. The mean age of the cohort was
74 ± 10, and the majority of patients were male (686,
67.7%). There were 448 patients with LVEF < 40% and 565
with LVEF ≥ 40%. The majority of patients were receiving HF
medications including ACE/ARB (59.9%) and beta-blocker
therapy (58.8%). The median NLR was 4.29. The majority of
patients (964, 94.8%) had their NLR measured within 7 days
of their index hospitalization (median time 0 days, interquar-
tile range 0–0).
Association between NLR and clinical outcomes in
GoDARTS
Associations between NLR and outcomes in GODARTS
patients are summarized in Table 4. Over the median
follow-up period of 22 months, the primary outcome oc-
curred in 759 individuals, including 641 deaths and 409 HF
hospitalizations. After multivariable adjustment, NLR was
significantly associated with increased incidence of the
Table 3 Association of inflammatory biomarkers with the primary outcome adjusted for the BIOSTAT-CHF model
Biomarker
Hazard ratio per SD
increase (95% CI) (adjusted
for BIOSTAT risk score only) P-value
Hazard ratio per SD increase (adjusted
for BIOSTAT risk score + significant
inflammatory biomarkers) P-value
NLR 1.18 (1.11–1.25) <0.001 1.15 (1.07–1.24) <0.001
CSTB 1.15 (1.06–1.24) <0.001 1.10 (0.98–1.24) 0.12
IL6 1.16 (1.08–1.26) <0.001 1.10 (1.00–1.21) 0.039
IL17RA 1.13 (1.04–1.22) 0.002 1.06 (0.96–1.18) 0.22
IL18BP 1.07 (0.98–1.16) 0.13
IL1RT1 1.10 (1.02–1.20) 0.019 0.95 (0.83–1.08) 0.44
IL1RT2 1.06 (0.98–1.14) 0.17
IL2RA 1.07 (0.99–1.17) 0.09
IL6RA 0.98 (0.91–1.05) 0.56
MCP1 1.04 (0.97–1.12) 0.24
MPO 1.06 (0.99–1.14) 0.11
OPG 1.12 (1.04–1.22) 0.005 1.00 (0.89–1.13) 0.99
TNFR1 1.17 (1.07–1.28) <0.001 1.16 (0.84–1.61) 0.38
TNFR2 1.13 (1.03–1.23) 0.006 0.70 (0.54–0.92) 0.009
TNFRSF10C 1.03 (0.96–1.12) 0.40
TNFRSF14 1.13 (1.04–1.22) 0.005 1.17 (0.88–1.54) 0.28
TNFSF13B 1.17 (1.09–1.27) <0.001 1.17 (1.06–1.29) 0.001
UPA 1.04 (0.96–1.12) 0.37
CSTB, cystatin-B; IL17RA, interleukin 17 receptor A; IL18BP, interleukin 18 binding protein; IL1RT1, interleukin 1 receptor type 1; IL1RT2,
interleukin 1 receptor type 2; IL2RA, interleukin 2 receptor subunit alpha; IL6, interleukin 6; IL6RA, interleukin 6 receptor subunit alpha;
MCP1, monocyte chemotactic protein 1; MPO, myeloperoxidase; OPG, osteoprotegerin; NLR, neutrophil-to-lymphocyte ratio; TNFR1, tu-
mour necrosis factor receptor 1; TNFR2, tumour necrosis factor receptor 2; TNFRSF14, tumour necrosis factor receptor superfamily mem-
ber 14; TNFSF13B, tumour necrosis factor ligand superfamily member 13B; TNRSF10C, tumour necrosis factor receptor superfamily
member 10C; UPA, urokinase plasminogen activator.
Adjusted for the BIOSTAT-CHF risk model, which includes age, HF hospitalization in the previous year, peripheral oedema, systolic blood
pressure, estimated glomerular filtration rate, urea, N-terminal pro-brain natriuretic peptide, haemoglobin, high-density lipoprotein cho-
lesterol, sodium, and beta-blocker use.
Bold indicates P < 0.05.
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primary outcome (HR 1.20 per SD increase; 95% CI 1.13–1.27,
P < 0.001). NLR was also significantly associated with in-
creased all-cause mortality (HR 1.20 per SD increase; 95% CI
1.13–1.27, P < 0.001). In line with the BIOSTAT-CHF cohort,
NLR was significantly associated with the primary outcome
regardless of LVEF (LVEF < 40%: HR 1.20 per SD increase;
95% CI 1.11–1.30, P < 0.001) and HFpEF patients (HR 1.27
per SD increase; 95% CI 1.15–1.39, P < 0.001).
When the cohort was stratified into tertiles of NLR,
after multivariable adjustment for age, gender, diabetes,
cholesterol, blood pressure, smoking status, ACEI/ARB
and beta-blocker use and prior myocardial infarction,
there was a significant stepwise association between higher
NLR and increased likelihood of the primary outcome
(Tertile 2: HR 1.27; 95% CI 1.06–1.53, P = 0.011; Tertile 3:
HR 1.85; 95% CI 1.54–2.22, P < 0.001), with similar results
for mortality alone (Figure S2). These results were similar in
patients with LVEF ≥ 40% and those with LVEF < 40%.
Three hundred seven individuals had not died or had a HF
hospitalization at 6 months and had an available NLR at this
time point (116 LVEF < 40%, 191 LVEF ≥ 40%; 175 male).
Median NLR in this subset of patients was 3.23 (interquartile
range 0.62–5.84). NLR had decreased compared with baseline
in 209 patients (68.1%). After adjustment, a decrease in NLR
at 6 months was significantly associated with reduced inci-
dence of mortality and/or HF hospitalization (HR 0.75; 95%
CI 0.57–0.98, P = 0.036). The association between decrease
in NLR at 6 months and improved outcome was similar
Table 4 Association between tertiles of NLR and outcomes stratified in GoDARTS
Whole cohort (n = 1013) LVEF < 40% (n = 448) LVEF ≥ 40% (n = 565)
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Mortality and/or HF hospitalization
NLR per SD increase 1.20 (1.13–1.27) <0.001 1.20 (1.11–1.30) <0.001 1.27 (1.15–1.39) <0.001
Tertile 1 Baseline Baseline Baseline
Tertile 2 1.27 (1.06–1.53) 0.011 1.62 (1.22–2.13) <0.001 1.06 (0.82–1.36) 0.68
Tertile 3 1.85 (1.54–2.22) <0.001 2.17 (1.63–2.90) <0.001 1.76 (1.38–2.23) <0.001
Mortality
NLR per SD increase 1.20 (1.13–1.27) <0.001 1.17 (1.07–1.28) <0.001 1.29 (1.17–1.42) <0.001
Tertile 1 Baseline Baseline Baseline
Tertile 2 1.21 (0.99–1.49) 0.07 1.41 (1.03–1.94) 0.034 1.07 (0.82–1.40) 0.62
Tertile 3 1.86 (1.53–2.26) <0.001 2.12 (1.54–2.91) <0.001 1.71 (1.33–2.21) <0.001
Adjusted for age, gender, diabetes, cholesterol, blood pressure, smoking status, ACEI/ARB and beta-blocker use at the time of diagnosis,
and prior myocardial infarction
Bold indicates P < 0.05.
Figure 3 Outcomes in the GoDARTS cohort stratified by change in NLR at 6 months in HFrEF and HFpEF. Kaplan–Meier analysis of mortality/HF hos-
pitalization stratified by NLR change at 6 months in GoDARTS.
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regardless of LVEF (LVEF < 40%: HR 0.62; 95% CI 0.38–0.99,
P = 0.044; LVEF ≥ 40%: HR 0.70; 95% CI 0.48–1.02,
P = 0.065, interaction P-value 0.60) (Figure 3).
Discussion
In this study, we identified several findings. Most importantly,
we found that increased NLR was significantly associated with
clinical outcomes in patients with new-onset or worsening
HFrEF and HFpEF and validated this in a second independent
cohort. We also found that NLR was significantly correlated
with several established biomarkers related to inflammatory
pathways in HF. In addition, NLR was also significantly corre-
lated with NT-proBNP. Finally, we have shown that a decrease
in NLR at 6 months was associated with reduced incidence of
mortality/HF hospitalization.
Our findings add to the accumulating evidence base show-
ing the value of NLR as a prognostic marker in cardiovascular
disease.9–11 In HF patients specifically, previous studies have
demonstrated the relationship between NLR and outcome
in patients with acute decompensated HF and HF patients
awaiting transplant.13,14,31,32 Boralkar et al.33 investigated
443 patients hospitalized with acute HF and preserved ejec-
tion fraction and found that NLR was associated with
all-cause mortality. Yan et al.34 investigated 1335 elderly pa-
tients with chronic HF and found that raised NLR was associ-
ated with major cardiac events including cardiac death and
rehospitalization. Our multicentre study composed of two
large independent cohorts extends these findings by demon-
strating the association of NLR with adverse outcomes in
both HFrEF and HFpEF patients in both an inpatient and out-
patient setting over a long follow-up period. We have also
shown that NLR is higher in inpatients than outpatients, sug-
gesting that inflammation may play a part in HF decompensa-
tions. Supporting this, we found that elevated NLR was also
associated with higher NT-proBNP and markers of congestion
and worse NYHA functional class, despite similar LVEF and re-
gardless of inpatient vs. outpatient setting.
We demonstrated a strong association between NLR and
various biomarkers related to inflammatory pathways in HF
that have been shown to independently predict prognosis in
HF.4–7,30 These associations have been previously identified
in other conditions such as end-stage renal disease,35 and
we have shown for the first time that this correlation is
consistent in HF. The concept of NLR acting as a routinely
available parameter of inflammatory status, correlating with
other established inflammatory biomarkers and being inde-
pendently associated with outcome with evidence of
incremental prognostic value in addition to NT-proBNP, is par-
ticularly appealing for clinical translation. NLR reflects both
neutrophilia, typically representative of non-specific inflam-
mation, and lymphopaenia, a marker of physiological stress
thought to be caused by programmed cell death as a result
of oxidative stress and elevated plasma cortisol levels.9 There
are two main pathways by which elevated NLR could be
associated with worse outcome in HF: First, increased release
of pro-inflammatory cytokines by neutrophils could impair
myocardial function by direct damage.36 Second, elevated
NLR might also be reflective of increased sympathetic tone,
one of the key pathophysiological mechanisms underlying
HF.37 We also showed that NLR seems to have additional
value compared with just neutrophil or lymphocyte count
alone. NLR was associated with outcome independent of
markers of congestion that we have previously reported in
BIOSTAT-CHF but was more strongly associated with progno-
sis than interleukin 6 (and any other specific inflammatory
markers). Inflammation in HF is likely to be the result of
several pathways, and so, a biomarker such as NLR that can
identify these may be more useful than one at the end of a
specific pathophysiological pathway. Indeed, supporting this,
we found that NLR did provide improve discrimination to
the BIOSTAT-CHF risk model, whereas interleukin 6 did
not.30 It is also notable there was no significant interaction be-
tween the prognostic association of NLR and LVEF, though el-
evated NLR was more strongly associated with the primary
outcome in HFrEF. Inflammation is strongly hypothesized to
play an important role in HFpEF, but our findings suggest that
it may also be important in HFrEF, and further studies should
be performed to elucidate this more clearly and in particular
whether elevated NLR and inflammation is truly an underlying
driver of HF or simply a marker of advanced disease.2,3,38,39
Our finding of improved outcome in patients with de-
creased NLR at 6 months post-HF hospitalization is particu-
larly interesting as it may suggest a possibility for targeting
inflammation, particularly in HFpEF, where there are no
evidence-based therapies as yet. Previous trials involving
anti-inflammatory targeting in HF have been largely unsuc-
cessful, although many of these trials have been in HFrEF pa-
tients without specifically targeting those with evidence of
high levels of systemic inflammation.40–43 In RENEWAL, the
soluble TNF antagonist etanercept was found to have no
clinical benefit on death of HF hospitalization in HFrEF
patients.40 This study reported soon after the ATTACH trial,
in which a similar approach using infliximab in HFrEF patients
also did not show any benefit and in fact potentially had
deleterious effects at higher doses.44 Conversely, in CANTOS,
increasing doses of canakinumab (an IL-1β inhibitor) were as-
sociated with fewer HF hospitalizations.45 Patients in the
canakinumab arm who achieved lower levels of high-sensitiv-
ity C-reactive protein (hs-CRP) had improved outcome com-
pared with those who did not achieve lower levels or
those assigned to placebo, although only 20% of patients
in CANTOS had a history of HF at baseline. NLR may have
an advantage over other markers such as hs-CRP as it is
more readily available. In particular, use of a marker such
as NLR might be used for patient selection in future trials
of anti-inflammatory therapies by identifying individuals with
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13424
high levels of inflammation more likely to benefit from
therapeutic anti-inflammatory intervention.
Our study had a number of limitations. First, due to the
observational study design and its inherent limitations, our
findings serve to highlight the association between NLR and
adverse outcome but cannot infer causation, although our
study is strengthened by the use of two separate cohorts in-
cluding both HFrEF and HFpEF. We do recognize that there
were some differences between the cohorts, such as the fact
that the GoDARTS cohort were all hospitalized patients
whereas BIOSTAT-CHF also included outpatients, and differ-
ences in ejection fraction measurements. NLR was recorded
at baseline but not systematically during follow-up, and so,
we cannot exclude indication bias. Also, neutrophils do have
rapid turnover and may be influenced by acute clinical
events, so serial measurements at baseline might have been
useful, although NLR was actually more strongly associated
with outcome in outpatients in the BIOSTAT cohort. We did
not systematically assess for the presence of undiagnosed
malignancy in either cohort (e.g. with imaging), although
there was no evidence of active malignancy in the electronic
medical records of the patients. Nevertheless, we cannot
completely exclude undiagnosed conditions that might affect
NLR such as malignancy or rheumatological conditions. We
did not measure other inflammatory markers such as
C-reactive protein or procalcitonin and did not perform other
tests such as chest x-rays to definitively exclude intercurrent
infection. Nevertheless, all patients in the BIOSTAT-CHF co-
hort had a clinical examination performed at baseline, and
the consistency of our results across two cohorts and in both
inpatients and outpatients does give further confidence that
our results were not just driven by the presence of concomi-
tant infection in all patients. Related to this, although pa-
tients with acute myocarditis were excluded, we did not
systematically assess for the presence of chronic myocarditis,
for example, with cardiovascular magnetic resonance imaging
or endomyocardial biopsy. There may also be selection bias,
and these results are not necessarily applicable to all HF pa-
tients, for example, hospitalized patients requiring haemody-
namic support. Finally, as the GoDARTS cohort data and some
BIOSTAT outcome data were obtained from electronic health
records, we were not able to conduct a similar multivariable
analysis using the BIOSTAT-CHF risk prediction model. Theo-
retically, central adjudication of events may have provided
more assurance around the documentation of HF hospitaliza-
tions, although use of electronic health records is well
established and provides good accuracy.23,46
Conclusion
In HFrEF and HFpEF patients, NLR was strongly associated
with biomarkers of inflammation and elevated levels were
significantly associated with adverse outcome independent
of other clinical variables. A decrease in NLR at 6 months
was significantly associated with improved outcome in HFpEF
patients. Future prospective randomized interventional stud-
ies are warranted to determine whether NLR can be used to
select HF patients at high risk who might benefit from
anti-inflammatory therapies or might even be a treatment
target in HF.
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